Literature DB >> 18692813

Tubal perforation by Essure: three different clinical presentations.

Josje Langenveld1, Sebastiaan Veersema, Marlies Y Bongers, Carolien A Koks.   

Abstract

OBJECTIVE: To assess the convenience and safety of Essure sterilization in an outpatient setting and the use of ultrasound as diagnostic tool for verification of proper placement for the 3-month follow-up.
DESIGN: Prospective cohort study.
SETTING: Teaching hospital department of obstetrics and gynecology. PATIENT(S): Female patients with a request for permanent tubal sterilization. INTERVENTION(S): Essure sterilization. MAIN OUTCOME MEASURE(S): Bilateral tubal occlusion after Essure sterilization and complication rate. RESULT(S): A total of 149 patients were scheduled for Essure sterilization. Microinsert placement was attempted in 143 patients. Bilateral placement of the device was successful in 95% (95% confidence interval [CI] 92%-99%). Seven attempts were unsuccessful. The complication rate was 2% (n = 3), and all involved a perforation. These three cases are discussed in detail. Vaginal ultrasound was conclusive in 91.7% (95% CI 87%-96%); two perforations were not recognized on the ultrasound. CONCLUSION(S): Essure sterilization is a safe and reliable sterilization method in an outpatient setting. Perforation of the device is the most frequent complication. Vaginal ultrasound is reliable for verification after an uncomplicated procedure. When the procedure is difficult (e.g., higher resistance, more pain then average, more time or more than two devices needed), a hysterosalpingogram should be performed.

Entities:  

Mesh:

Year:  2008        PMID: 18692813     DOI: 10.1016/j.fertnstert.2008.06.020

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

1.  Incidence of opioid-managed pelvic pain after hysteroscopic sterilization versus laparoscopic sterilization, US 2005-2012.

Authors:  Mitchell M Conover; Jennifer O Howell; Jennifer M Wu; Alan C Kinlaw; Nabarun Dasgupta; Michele Jonsson Funk
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-03-31       Impact factor: 2.890

2.  Clinical performance characteristics of the adiana® system for permanent contraception: the first year of commercial use.

Authors:  Seth J Herbst; Edward G Evantash
Journal:  Rev Obstet Gynecol       Date:  2010

3.  Tubal risk markers for failure to place transcervical sterilization coils.

Authors:  Ophra Leyser-Whalen; Mahta Rouhani; Mahbubur Rahman; Abbey B Berenson
Journal:  Contraception       Date:  2011-10-27       Impact factor: 3.375

4.  Hysterosalpingogram: an essential examination following Essure hysteroscopic sterilisation.

Authors:  V Shah; N Panay; R Williamson; A Hemingway
Journal:  Br J Radiol       Date:  2010-12-01       Impact factor: 3.039

5.  Discordant relationship between Essure microinsert position and tubal occlusion.

Authors:  Melody Y Hou
Journal:  BMJ Case Rep       Date:  2016-07-27

Review 6.  A Meta-Analysis of Bilateral Essure® Procedural Placement Success Rates on First Attempt.

Authors:  Gabriel Frietze; Ophra Leyser-Whalen; Mahbubur Rahman; Mahta Rouhani; Abbey B Berenson
Journal:  J Gynecol Surg       Date:  2015-12-01

Review 7.  Hysteroscopic tubal sterilization: an evidence-based analysis.

Authors:  K McMartin
Journal:  Ont Health Technol Assess Ser       Date:  2013-10-01

8.  Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US.

Authors:  Chi Y Bahk; Melanie Goshgarian; Krystal Donahue; Clark C Freifeld; Christopher M Menone; Carrie E Pierce; Harold Rodriguez; John S Brownstein; Robert Furberg; Nabarun Dasgupta
Journal:  Pharmaceut Med       Date:  2015-08-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.